Reasons Why Investors Should Consider Betting on Arvinas Stock
ARVN's first FDA-approved PROTAC degrader validates its technology, while a diverse pipeline targeting cancer and neurological disorders offers further growth potential.
ARVN - Arvinas, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$14.17
DETAILS
HIGH:
$20.00
LOW:
$10.00
MEDIAN:
$13.00
CONSENSUS:
$14.17
UPSIDE:
103.30%
Stock News
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson's Disease
– Data showed improvements in an objective measure of impaired eye movement associated with Parkinson's disease, with a correlation between reductions in LRRK2 cerebrospinal fluid (CSF) biomarkers to these changes in oculomotor function and changes in synaptic biomarkers –
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson's Disease and Movement Disorders®
NEW HAVEN, Conn., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that novel biomarker data from a Phase 1 clinical trial of ARV-102 in participants with Parkinson's disease will be presented as late-breaking oral and poster presentations at the 2026 International Congress of Parkinson's Disease and Movement Disorders® (MDS), taking place October 4-8, 2026, in Seoul, Korea.
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted an option to purchase 64,766 shares of common stock (the “Option Award”) and 42,388 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The Option Award and RSU Award were each granted as of September 28, 2026 (the “Grant Date”) in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas' stock incentive plan.
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate
– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors –
Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that that management will participate in fireside chats at the following upcoming investor conferences:
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted 45,696 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The RSU Award was granted as of August 31, 2026 (the “Grant Date”) and in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas' stock incentive plan.
Connor Clark & Lunn Investment Management Ltd. Invests $1.39 Million in Arvinas, Inc. $ARVN
Connor Clark and Lunn Investment Management Ltd. bought a new position in shares of Arvinas, Inc. (NASDAQ: ARVN) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 167,056 shares of the company's stock, valued at approximately $1,388,000. Connor
Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish
Arvinas receives a Buy rating upgrade, underpinned by Veppanu's FDA approval and a robust PROTAC platform. Despite Veppanu's approval for ESR1-mutated breast cancer, ARVN's share price remains near cash value, reflecting market skepticism about future revenues. ARVN's pipeline includes five early-stage programs and a Novartis-partnered asset, but high R&D costs and uncertain milestones temper near-term upside.
Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know
Arvinas (ARVN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Arvinas Q2 Earnings Call Highlights
Arvinas (NASDAQ: ARVN) said it is concentrating resources on its early-stage oncology and neurology pipeline after reaching several strategic milestones in the first half of 2026, including FDA approval of VEPPANU, the first approved PROTAC degrader, and an out-licensing agreement for the product with Rigel Pharmaceuticals. President and Chief Executive Officer Randy Teel said Rigel expects
Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript
Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript
Arvinas Q2 Earnings Call Highlights
Arvinas NASDAQ: ARVN said it is concentrating resources on its early-stage oncology and neurology pipeline after reaching several strategic milestones in the first half of 2026, including FDA approval of VEPPANU, the first approved PROTAC degrader, and an out-licensing agreement for the product with Rigel Pharmaceuticals.
Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates
Arvinas, Inc. (ARVN) came out with quarterly earnings of $2.58 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to a loss of $0.84 per share a year ago.
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader ), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals – – Anticipates sharing clinical data from three Phase 1 programs - ARV-393, ARV-102 and ARV-027 - over the next 12 months – – Presented promising preclinical data for HPK1 degrader program (ARV-6723) demonstrating the potential to overcome immune checkpoint inhibitor resistance in solid tumors – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn.
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review second quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, August 4, 2026 at 8:00 a.m. ET.
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data
Arvinas NASDAQ: ARVN management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that may require broader development resources.
Arvinas to Present at Jefferies Global Healthcare Conference
NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 9:55 a.m. ET.
Arvinas to Present at Jefferies Global Healthcare Conference
NEW HAVEN, Conn. , May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 9:55 a.
Price Targets
Arvinas price target lowered to $10 from $11 at Morgan Stanley
$10.00
(was $8.94)
Morgan Stanley
Arvinas price target lowered to $14 from $19 at Evercore ISI
$14.00
(was $8.95)
Evercore ISI
Arvinas price target raised to $12 from $11 at Wedbush
$12.00
(was $9.00)
Robert Driscoll
·
Wedbush
Wells downgrades Arvinas to Equal Weight, sees catalysts coming in 2027
$11.00
(was $8.86)
Wells Fargo
Arvinas price target raised to $18 from $16 at BTIG
$18.00
(was $9.57)
BTIG
Arvinas price target raised to $20 from $18 at Barclays
$20.00
(was $9.57)
Barclays
Truist Securities Reiterates Hold Rating on Arvinas Inc. (ARVN) amid positive Parkinson's data
$10.00
(was $10.96)
Srikripa Devarakonda
·
Truist Financial
Arvinas price target raised to $11 from $9 at Wedbush
$11.00
(was $12.37)
Wedbush
Arvinas price target raised to $18 from $16 at Barclays
$18.00
(was $11.90)
Barclays
Arvinas Inc. (ARVN) PT Raised to $14 at BTIG
$14.00
(was $9.59)
Jeet Mukherjee
·
BTIG
Arvinas downgraded to Sell from Neutral at Goldman Sachs
$6.00
(was $9.41)
Goldman Sachs
Arvinas price target raised to $16 from $14 at Piper Sandler
$16.00
(was $9.36)
Piper Sandler
Arvinas price target lowered to $10 from $16 at BTIG
$10.00
(was $7.92)
BTIG
Arvinas price target lowered to $14 from $16 at Stephens
$14.00
(was $7.75)
Sudan Loganathan
·
Stephens
Arvinas assumed with an Overweight at Barclays
$16.00
(was $7.64)
Barclays
Arvinas-Pfizer partnership dynamics may shift, says H.C. Wainwright
$24.00
(was $7.33)
Andrew Fein
·
H.C. Wainwright
Arvinas downgraded to Hold from Buy at Truist
$11.00
(was $7.63)
Srikripa Devarakonda
·
Truist Financial
Arvinas price target lowered to $16 from $69 at BTIG
$16.00
(was $7.72)
Jeet Mukherjee
·
BTIG
Arvinas price target lowered to $12 from $48 at Morgan Stanley
$12.00
(was $8.55)
Morgan Stanley
Arvinas price target lowered to $20 from $82 at BMO Capital
$20.00
(was $8.43)
Etzer Darout
·
BMO Capital